Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.
about
Muscle-invasive urothelial bladder cancer: an update on systemic therapyRole of systemic chemotherapy in urothelial urinary bladder cancerMicrotubule-binding agents: a dynamic field of cancer therapeutics.Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgeryElevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial CarcinomaTime from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trialsSystemic therapy for bladder cancer finally comes into a new age.Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialVinflunine in routine clinical practice for the treatment of advanced or metastatic urothelial cell carcinoma - data from a prospective, multicenter experience.Paclitaxel plus doxorubicin chemotherapy as second-line therapy in patients with advanced urothelial carcinoma pretreated with platinum plus gemcitabine chemotherapy.Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study.An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancerPhase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma.Comparison of single agent versus combined chemotherapy in previously treated patients with advanced urothelial carcinoma: a meta-analysis.Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) as second-line therapy for patients with advanced urothelial cancer.Recent advances in treatment of advanced urothelial carcinoma.Systemic therapy in bladder cancerNaturally Occurring Canine Invasive Urinary Bladder Cancer: A Complementary Animal Model to Improve the Success Rate in Human Clinical Trials of New Cancer Drugs.Phase II study of everolimus in metastatic urothelial cancer.Resistance to nanoparticle albumin-bound paclitaxel is mediated by ABCB1 in urothelial cancer cells.FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01-2014).Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial.A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors.Saudi oncology society and Saudi urology association combined clinical management guidelines for urothelial urinary bladder cancer.Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice.Melphalan-flufenamide is cytotoxic and potentiates treatment with chemotherapy and the Src inhibitor dasatinib in urothelial carcinoma.Systemic therapy for bladder cancer - a medical oncologist's perspective.First- and second-line therapy for metastatic urothelial carcinoma of the bladderFool's gold, lost treasures, and the randomized clinical trial.Current therapeutic strategies for invasive and metastatic bladder cancer.Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature.How to manage intravenous vinflunine in cancer patients with renal impairment: results of a pharmacokinetic and tolerability phase I study.Chemotherapy in advanced bladder cancer: current status and futureMetastatic bladder cancer: a review of current managementThe safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experienceSalvage systemic therapy for advanced urothelial carcinoma: on the cusp of a sea change?Conditional Survival in de novo Metastatic Urothelial CarcinomaCisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy
P2860
Q26775780-9FDA62DC-E2F1-4219-8350-663D3D82699AQ27010323-EC95C2B4-4B95-4EEA-BAE5-C2D7B0E27804Q27690249-98B9F97A-AD8F-40DF-865B-0B0676CBEEFAQ28074930-27385C4B-5E2A-4694-88EF-700EFF716025Q28084715-BB8597A5-F63F-4F71-A4D7-5FD1640F0F43Q28280571-15DF8092-1123-4953-8E1F-DDF6D6E40C7FQ30249047-236C3EC2-2D05-4FE1-B3A6-D75DAF0BFC76Q30277192-93F37D98-5ABC-48BF-89CB-6BDFF5E345FEQ30964757-93E42BF2-E2D3-434E-8133-D7B279C5BBD5Q33403679-501DEC9E-3F26-4BDE-999E-D10350243053Q33410627-D7168589-5C5D-46C1-9975-DA90D324C8D5Q33412123-4232653D-630A-4BC6-B49F-1C93419E6BF2Q33426694-0F71B8D5-4F18-4B51-A5E1-8CCB5048C583Q33431220-819EF78F-8FD6-48E9-860A-7879E6F96A41Q33433861-0608D016-B5EF-48FA-90B5-5A7F8E349E82Q33565845-E38F893E-016E-4B56-A85B-1883CECCC133Q33578564-05A45CEF-53B8-42AD-856D-C62495E24B8DQ33593041-577B1C7D-7405-441E-801A-683109772B42Q33606604-269F77DB-9A32-41F2-9048-5D16B069EE22Q33751197-5EB82030-3404-452F-969A-F88FC0DB7D1BQ33793541-58F939B8-CFCC-4A32-80B1-DBBFC37FF263Q33919252-36BE06DE-1AEE-48F3-8B57-5FB3FACE3FDFQ33923405-BE07757F-7175-4A2C-90A5-DD631C32FBCEQ34188703-6AE92A15-162F-4799-91D4-AED3CABD7FACQ34336217-C8EE786E-CB36-44E2-946E-CDF74B3B5472Q34437299-B17CDCD3-DE07-4818-90B8-C2D0231BAB46Q34438928-9118333D-51AE-4F0F-BE74-9B31B18F12D4Q34511534-19B0A285-9B68-437B-9569-34378DDAF548Q34516731-904567CC-BD8E-48C5-A3D2-4441139834D6Q34541463-D620265B-C482-4BA7-9A92-AA286CA69A9DQ34669260-EA35FEC7-F023-42CE-8948-17503993EBFCQ35128721-F3A0AFD9-8D3E-4874-82EA-8A3144086C1FQ35180823-3C66902E-E22F-4DAB-87F6-2CD2C54B9630Q35211441-D544384E-4A02-4860-9F0A-12E05C1E2F5FQ35227771-64183A95-9969-4FB1-8F2E-1C4B48FD1378Q35394211-9E54E5E0-D6B4-4D3F-8512-8AB3B69A8310Q35586693-21CB151B-ECB8-4E71-9088-96E90DB78152Q35586740-771CABF5-7051-40E8-9C72-F9717109F64BQ35756105-DF40DFE4-BDC6-4DD1-A38A-7F8987F5B152Q35771672-8A9532AC-4E39-42AD-B217-4F1CC835F768
P2860
Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Phase III trial of vinflunine ...... inoma of the urothelial tract.
@ast
Phase III trial of vinflunine ...... inoma of the urothelial tract.
@en
Phase III trial of vinflunine ...... inoma of the urothelial tract.
@nl
type
label
Phase III trial of vinflunine ...... inoma of the urothelial tract.
@ast
Phase III trial of vinflunine ...... inoma of the urothelial tract.
@en
Phase III trial of vinflunine ...... inoma of the urothelial tract.
@nl
prefLabel
Phase III trial of vinflunine ...... inoma of the urothelial tract.
@ast
Phase III trial of vinflunine ...... inoma of the urothelial tract.
@en
Phase III trial of vinflunine ...... inoma of the urothelial tract.
@nl
P2093
P50
P356
P1476
Phase III trial of vinflunine ...... inoma of the urothelial tract.
@en
P2093
Armelle Caty
Boris Komyakov
Christine Théodore
Eric Winquist
François-Michel Delgado
Hans von der Maase
Joaquim Bellmunt
Lisa Sengelov
Nassim Morsli
Oleg Karyakin
P304
P356
10.1200/JCO.2008.20.5534
P407
P577
2009-08-17T00:00:00Z